ABEO ABEONA THERAPEUTICS INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 318306 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-175.9%
TTM EPS YoY-189.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin65.1%
Operating margin-186.1%
Net margin-160.3%
FCF margin-170.1%
EBITDA margin-178.5%
Returns
ROE-42.1%
ROA-31.0%
ROIC (approx.)-59.9%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets26.8%
Debt / equity0.19x
Current ratio5.69x
Interest coverage-24.47x
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio0.5%
Payout ratio—
Capex / revenue7.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $5.82M | — |
| Cost of revenue | $1.53M | — |
| Gross profit | $4.29M | — |
| R&D expense | $26.81M | $34.36M |
| SG&A expense | $65.03M | $29.85M |
| Operating income | -$89.45M | -$64.21M |
| Interest expense | $3.74M | $4.21M |
| Pretax income | $71.28M | -$63.73M |
| Income tax | $100,000 | — |
| Net income | $71.18M | -$63.73M |
| EBITDA | -$86.90M | -$62.21M |
| EPS (basic) | 1.34 | -1.55 |
| EPS (diluted) | 1.01 | -1.55 |
| Weighted avg. shares (diluted) | 66.14M | 41.05M |
| Balance sheet | ||
| Cash & equivalents | $78.44M | $23.36M |
| Short-term investments | $112.97M | $74.36M |
| Receivables | $6.15M | — |
| Inventory | $5.49M | — |
| Current assets | $204.91M | $100.85M |
| PP&E, net | $9.92M | $4.43M |
| Total assets | $219.57M | $108.93M |
| Current liabilities | $29.57M | $16.59M |
| Short-term debt | $12.22M | $5.93M |
| Long-term debt | $7.81M | $13.04M |
| Total debt | $20.04M | $18.96M |
| Total liabilities | $60.35M | $64.90M |
| Shareholders' equity | $159.22M | $44.03M |
| Net debt | -$58.40M | -$4.39M |
| Shares outstanding | 55.04M | 45.64M |
| Cash flow statement | ||
| Operating cash flow | -$76.33M | -$56.02M |
| Capital expenditure | $7.97M | $2.45M |
| Free cash flow | -$84.30M | -$58.46M |
| Investing cash flow | $105.03M | -$39.24M |
| Financing cash flow | $26.04M | $104.14M |
| Depreciation & amortization | $2.55M | $2.00M |
| Stock-based compensation | $10.78M | $6.63M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.